CN115521373B - Triple helix recombinant humanized type I collagen, preparation method and application thereof - Google Patents
Triple helix recombinant humanized type I collagen, preparation method and application thereof Download PDFInfo
- Publication number
- CN115521373B CN115521373B CN202210630810.XA CN202210630810A CN115521373B CN 115521373 B CN115521373 B CN 115521373B CN 202210630810 A CN202210630810 A CN 202210630810A CN 115521373 B CN115521373 B CN 115521373B
- Authority
- CN
- China
- Prior art keywords
- collagen
- pro
- gly
- recombinant humanized
- recombinant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108010022452 Collagen Type I Proteins 0.000 title claims abstract description 88
- 102000012422 Collagen Type I Human genes 0.000 title claims abstract description 88
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 108010035532 Collagen Proteins 0.000 claims abstract description 86
- 102000008186 Collagen Human genes 0.000 claims abstract description 85
- 229920001436 collagen Polymers 0.000 claims abstract description 85
- 241000894006 Bacteria Species 0.000 claims abstract description 18
- 210000000988 bone and bone Anatomy 0.000 claims abstract description 9
- 238000000034 method Methods 0.000 claims abstract description 9
- 239000012620 biological material Substances 0.000 claims abstract description 8
- 210000000845 cartilage Anatomy 0.000 claims abstract description 6
- 210000004087 cornea Anatomy 0.000 claims abstract description 6
- 239000002537 cosmetic Substances 0.000 claims abstract description 6
- 239000007943 implant Substances 0.000 claims abstract description 6
- 230000008439 repair process Effects 0.000 claims abstract description 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 6
- 239000002243 precursor Substances 0.000 claims description 26
- 108090000623 proteins and genes Proteins 0.000 claims description 18
- 239000004365 Protease Substances 0.000 claims description 12
- 108091005804 Peptidases Proteins 0.000 claims description 8
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 8
- 230000001580 bacterial effect Effects 0.000 claims description 7
- 238000010353 genetic engineering Methods 0.000 claims description 5
- 108090000284 Pepsin A Proteins 0.000 claims description 4
- 102000057297 Pepsin A Human genes 0.000 claims description 4
- 229940111202 pepsin Drugs 0.000 claims description 4
- 239000006228 supernatant Substances 0.000 claims description 3
- 230000002194 synthesizing effect Effects 0.000 claims description 3
- 230000001131 transforming effect Effects 0.000 claims description 3
- 239000002244 precipitate Substances 0.000 claims description 2
- 239000000835 fiber Substances 0.000 abstract description 9
- 210000001626 skin fibroblast Anatomy 0.000 abstract description 8
- 230000035755 proliferation Effects 0.000 abstract description 7
- 235000013305 food Nutrition 0.000 abstract description 5
- 230000036541 health Effects 0.000 abstract description 5
- -1 medical instrument Substances 0.000 abstract description 5
- 230000005012 migration Effects 0.000 abstract description 5
- 238000013508 migration Methods 0.000 abstract description 5
- 238000009776 industrial production Methods 0.000 abstract description 4
- 230000008569 process Effects 0.000 abstract description 3
- 108010014614 prolyl-glycyl-proline Proteins 0.000 description 24
- 150000001413 amino acids Chemical group 0.000 description 17
- OOCFXNOVSLSHAB-IUCAKERBSA-N Gly-Pro-Pro Chemical compound NCC(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 OOCFXNOVSLSHAB-IUCAKERBSA-N 0.000 description 14
- KZNQNBZMBZJQJO-UHFFFAOYSA-N N-glycyl-L-proline Natural products NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 description 12
- 108010029020 prolylglycine Proteins 0.000 description 12
- BRPMXFSTKXXNHF-IUCAKERBSA-N (2s)-1-[2-[[(2s)-pyrrolidine-2-carbonyl]amino]acetyl]pyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H]1NCCC1 BRPMXFSTKXXNHF-IUCAKERBSA-N 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- KKBWDNZXYLGJEY-UHFFFAOYSA-N Gly-Arg-Pro Natural products NCC(=O)NC(CCNC(=N)N)C(=O)N1CCCC1C(=O)O KKBWDNZXYLGJEY-UHFFFAOYSA-N 0.000 description 8
- 108010087846 prolyl-prolyl-glycine Proteins 0.000 description 8
- 239000000243 solution Substances 0.000 description 7
- CLNJSLSHKJECME-BQBZGAKWSA-N Pro-Gly-Ala Chemical compound OC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H]1CCCN1 CLNJSLSHKJECME-BQBZGAKWSA-N 0.000 description 6
- 108010047495 alanylglycine Proteins 0.000 description 6
- 108010009111 arginyl-glycyl-glutamic acid Proteins 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 235000019419 proteases Nutrition 0.000 description 6
- 241000283690 Bos taurus Species 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- DHDOADIPGZTAHT-YUMQZZPRSA-N Gly-Glu-Arg Chemical compound NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(O)=O)CCCN=C(N)N DHDOADIPGZTAHT-YUMQZZPRSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 230000021164 cell adhesion Effects 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- AUFHLLPVPSMEOG-YUMQZZPRSA-N Arg-Gly-Glu Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(O)=O AUFHLLPVPSMEOG-YUMQZZPRSA-N 0.000 description 4
- PUUYVMYCMIWHFE-BQBZGAKWSA-N Gly-Ala-Arg Chemical compound NCC(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N PUUYVMYCMIWHFE-BQBZGAKWSA-N 0.000 description 4
- VXKCPBPQEKKERH-IUCAKERBSA-N Gly-Arg-Pro Chemical compound NC(N)=NCCC[C@H](NC(=O)CN)C(=O)N1CCC[C@H]1C(O)=O VXKCPBPQEKKERH-IUCAKERBSA-N 0.000 description 4
- MOJKRXIRAZPZLW-WDSKDSINSA-N Gly-Glu-Ala Chemical compound [H]NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O MOJKRXIRAZPZLW-WDSKDSINSA-N 0.000 description 4
- UUYBFNKHOCJCHT-VHSXEESVSA-N Gly-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)CN UUYBFNKHOCJCHT-VHSXEESVSA-N 0.000 description 4
- CAVKXZMMDNOZJU-UHFFFAOYSA-N Gly-Pro-Ala-Gly-Pro Natural products C1CCC(C(O)=O)N1C(=O)CNC(=O)C(C)NC(=O)C1CCCN1C(=O)CN CAVKXZMMDNOZJU-UHFFFAOYSA-N 0.000 description 4
- UGTHTQWIQKEDEH-BQBZGAKWSA-N L-alanyl-L-prolylglycine zwitterion Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O UGTHTQWIQKEDEH-BQBZGAKWSA-N 0.000 description 4
- UCBPDSYUVAAHCD-UWVGGRQHSA-N Leu-Pro-Gly Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O UCBPDSYUVAAHCD-UWVGGRQHSA-N 0.000 description 4
- KIZQGKLMXKGDIV-BQBZGAKWSA-N Pro-Ala-Gly Chemical compound OC(=O)CNC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1 KIZQGKLMXKGDIV-BQBZGAKWSA-N 0.000 description 4
- BNBBNGZZKQUWCD-IUCAKERBSA-N Pro-Arg-Gly Chemical compound NC(N)=NCCC[C@@H](C(=O)NCC(O)=O)NC(=O)[C@@H]1CCCN1 BNBBNGZZKQUWCD-IUCAKERBSA-N 0.000 description 4
- VYWNORHENYEQDW-YUMQZZPRSA-N Pro-Gly-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H]1CCCN1 VYWNORHENYEQDW-YUMQZZPRSA-N 0.000 description 4
- LEIKGVHQTKHOLM-IUCAKERBSA-N Pro-Pro-Gly Chemical compound OC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 LEIKGVHQTKHOLM-IUCAKERBSA-N 0.000 description 4
- 108010069020 alanyl-prolyl-glycine Proteins 0.000 description 4
- 108010091092 arginyl-glycyl-proline Proteins 0.000 description 4
- 230000012292 cell migration Effects 0.000 description 4
- 238000001142 circular dichroism spectrum Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 4
- JYPCXBJRLBHWME-UHFFFAOYSA-N glycyl-L-prolyl-L-arginine Natural products NCC(=O)N1CCCC1C(=O)NC(CCCN=C(N)N)C(O)=O JYPCXBJRLBHWME-UHFFFAOYSA-N 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 108010064235 lysylglycine Proteins 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- JBGSZRYCXBPWGX-BQBZGAKWSA-N Ala-Arg-Gly Chemical compound OC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](N)C)CCCN=C(N)N JBGSZRYCXBPWGX-BQBZGAKWSA-N 0.000 description 2
- IFTVANMRTIHKML-WDSKDSINSA-N Ala-Gln-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(O)=O IFTVANMRTIHKML-WDSKDSINSA-N 0.000 description 2
- ZVFVBBGVOILKPO-WHFBIAKZSA-N Ala-Gly-Ala Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@@H](C)C(O)=O ZVFVBBGVOILKPO-WHFBIAKZSA-N 0.000 description 2
- WGDNWOMKBUXFHR-BQBZGAKWSA-N Ala-Gly-Arg Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCCN=C(N)N WGDNWOMKBUXFHR-BQBZGAKWSA-N 0.000 description 2
- PCIFXPRIFWKWLK-YUMQZZPRSA-N Ala-Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)[C@H](C)N PCIFXPRIFWKWLK-YUMQZZPRSA-N 0.000 description 2
- AQPVUEJJARLJHB-BQBZGAKWSA-N Arg-Gly-Ala Chemical compound OC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](N)CCCN=C(N)N AQPVUEJJARLJHB-BQBZGAKWSA-N 0.000 description 2
- HQIZDMIGUJOSNI-IUCAKERBSA-N Arg-Gly-Arg Chemical compound N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O HQIZDMIGUJOSNI-IUCAKERBSA-N 0.000 description 2
- OQCWXQJLCDPRHV-UWVGGRQHSA-N Arg-Gly-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC(C)C)C(O)=O OQCWXQJLCDPRHV-UWVGGRQHSA-N 0.000 description 2
- ZATRYQNPUHGXCU-DTWKUNHWSA-N Arg-Gly-Pro Chemical compound C1C[C@@H](N(C1)C(=O)CNC(=O)[C@H](CCCN=C(N)N)N)C(=O)O ZATRYQNPUHGXCU-DTWKUNHWSA-N 0.000 description 2
- NKNILFJYKKHBKE-WPRPVWTQSA-N Arg-Gly-Val Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O NKNILFJYKKHBKE-WPRPVWTQSA-N 0.000 description 2
- FSNVAJOPUDVQAR-AVGNSLFASA-N Arg-Lys-Arg Chemical compound NC(=N)NCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O FSNVAJOPUDVQAR-AVGNSLFASA-N 0.000 description 2
- ZJIFRAPZHAGLGR-MELADBBJSA-N Asn-Phe-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(=O)N)N)C(=O)O ZJIFRAPZHAGLGR-MELADBBJSA-N 0.000 description 2
- XHTUGJCAEYOZOR-UBHSHLNASA-N Asn-Ser-Trp Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O XHTUGJCAEYOZOR-UBHSHLNASA-N 0.000 description 2
- XAJRHVUUVUPFQL-ACZMJKKPSA-N Asp-Glu-Asp Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O XAJRHVUUVUPFQL-ACZMJKKPSA-N 0.000 description 2
- HSWYMWGDMPLTTH-FXQIFTODSA-N Asp-Glu-Gln Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O HSWYMWGDMPLTTH-FXQIFTODSA-N 0.000 description 2
- LDGUZSIPGSPBJP-XVYDVKMFSA-N Asp-His-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](CC(=O)O)N LDGUZSIPGSPBJP-XVYDVKMFSA-N 0.000 description 2
- QNMKWNONJGKJJC-NHCYSSNCSA-N Asp-Leu-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O QNMKWNONJGKJJC-NHCYSSNCSA-N 0.000 description 2
- 108010004032 Bromelains Proteins 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- BLOXULLYFRGYKZ-GUBZILKMSA-N Gln-Glu-Arg Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O BLOXULLYFRGYKZ-GUBZILKMSA-N 0.000 description 2
- PNENQZWRFMUZOM-DCAQKATOSA-N Gln-Glu-Leu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O PNENQZWRFMUZOM-DCAQKATOSA-N 0.000 description 2
- VSXBYIJUAXPAAL-WDSKDSINSA-N Gln-Gly-Ala Chemical compound OC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](N)CCC(N)=O VSXBYIJUAXPAAL-WDSKDSINSA-N 0.000 description 2
- BJPPYOMRAVLXBY-YUMQZZPRSA-N Gln-Met-Gly Chemical compound CSCC[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CCC(=O)N)N BJPPYOMRAVLXBY-YUMQZZPRSA-N 0.000 description 2
- NLKVNZUFDPWPNL-YUMQZZPRSA-N Glu-Arg-Gly Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O NLKVNZUFDPWPNL-YUMQZZPRSA-N 0.000 description 2
- OXEMJGCAJFFREE-FXQIFTODSA-N Glu-Gln-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(O)=O OXEMJGCAJFFREE-FXQIFTODSA-N 0.000 description 2
- SJPMNHCEWPTRBR-BQBZGAKWSA-N Glu-Glu-Gly Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O SJPMNHCEWPTRBR-BQBZGAKWSA-N 0.000 description 2
- LGYZYFFDELZWRS-DCAQKATOSA-N Glu-Glu-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CCC(O)=O LGYZYFFDELZWRS-DCAQKATOSA-N 0.000 description 2
- VGBSZQSKQRMLHD-MNXVOIDGSA-N Glu-Leu-Ile Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O VGBSZQSKQRMLHD-MNXVOIDGSA-N 0.000 description 2
- HRBYTAIBKPNZKQ-AVGNSLFASA-N Glu-Lys-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCC(O)=O HRBYTAIBKPNZKQ-AVGNSLFASA-N 0.000 description 2
- CQAHWYDHKUWYIX-YUMQZZPRSA-N Glu-Pro-Gly Chemical compound OC(=O)CC[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O CQAHWYDHKUWYIX-YUMQZZPRSA-N 0.000 description 2
- QXPRJQPCFXMCIY-NKWVEPMBSA-N Gly-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)CN QXPRJQPCFXMCIY-NKWVEPMBSA-N 0.000 description 2
- PMNHJLASAAWELO-FOHZUACHSA-N Gly-Asp-Thr Chemical compound [H]NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O PMNHJLASAAWELO-FOHZUACHSA-N 0.000 description 2
- YZPVGIVFMZLQMM-YUMQZZPRSA-N Gly-Gln-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)CN YZPVGIVFMZLQMM-YUMQZZPRSA-N 0.000 description 2
- SOEATRRYCIPEHA-BQBZGAKWSA-N Gly-Glu-Glu Chemical compound [H]NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O SOEATRRYCIPEHA-BQBZGAKWSA-N 0.000 description 2
- KAJAOGBVWCYGHZ-JTQLQIEISA-N Gly-Gly-Phe Chemical compound [NH3+]CC(=O)NCC(=O)N[C@H](C([O-])=O)CC1=CC=CC=C1 KAJAOGBVWCYGHZ-JTQLQIEISA-N 0.000 description 2
- VIIBEIQMLJEUJG-LAEOZQHASA-N Gly-Ile-Gln Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(O)=O VIIBEIQMLJEUJG-LAEOZQHASA-N 0.000 description 2
- CLNSYANKYVMZNM-UWVGGRQHSA-N Gly-Lys-Arg Chemical compound NCCCC[C@H](NC(=O)CN)C(=O)N[C@H](C(O)=O)CCCN=C(N)N CLNSYANKYVMZNM-UWVGGRQHSA-N 0.000 description 2
- IEGFSKKANYKBDU-QWHCGFSZSA-N Gly-Phe-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=CC=C2)NC(=O)CN)C(=O)O IEGFSKKANYKBDU-QWHCGFSZSA-N 0.000 description 2
- GGLIDLCEPDHEJO-BQBZGAKWSA-N Gly-Pro-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)CN GGLIDLCEPDHEJO-BQBZGAKWSA-N 0.000 description 2
- JYPCXBJRLBHWME-IUCAKERBSA-N Gly-Pro-Arg Chemical compound NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O JYPCXBJRLBHWME-IUCAKERBSA-N 0.000 description 2
- HJARVELKOSZUEW-YUMQZZPRSA-N Gly-Pro-Gln Chemical compound [H]NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(O)=O HJARVELKOSZUEW-YUMQZZPRSA-N 0.000 description 2
- POJJAZJHBGXEGM-YUMQZZPRSA-N Gly-Ser-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)CN POJJAZJHBGXEGM-YUMQZZPRSA-N 0.000 description 2
- ABPRMMYHROQBLY-NKWVEPMBSA-N Gly-Ser-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CO)NC(=O)CN)C(=O)O ABPRMMYHROQBLY-NKWVEPMBSA-N 0.000 description 2
- KWBISLAEQZUYIC-UWJYBYFXSA-N His-His-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](CC2=CN=CN2)N KWBISLAEQZUYIC-UWJYBYFXSA-N 0.000 description 2
- ZDSNOSQHMJBRQN-SRVKXCTJSA-N Leu-Asp-His Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N ZDSNOSQHMJBRQN-SRVKXCTJSA-N 0.000 description 2
- LXKNSJLSGPNHSK-KKUMJFAQSA-N Leu-Leu-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)O)N LXKNSJLSGPNHSK-KKUMJFAQSA-N 0.000 description 2
- GPJGFSFYBJGYRX-YUMQZZPRSA-N Lys-Gly-Asp Chemical compound NCCCC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC(O)=O GPJGFSFYBJGYRX-YUMQZZPRSA-N 0.000 description 2
- AIRZWUMAHCDDHR-KKUMJFAQSA-N Lys-Leu-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O AIRZWUMAHCDDHR-KKUMJFAQSA-N 0.000 description 2
- RXWPLVRJQNWXRQ-IHRRRGAJSA-N Met-His-His Chemical compound C([C@H](NC(=O)[C@@H](N)CCSC)C(=O)N[C@@H](CC=1N=CNC=1)C(O)=O)C1=CNC=N1 RXWPLVRJQNWXRQ-IHRRRGAJSA-N 0.000 description 2
- 108010079364 N-glycylalanine Proteins 0.000 description 2
- 108010002311 N-glycylglutamic acid Proteins 0.000 description 2
- 108090000526 Papain Proteins 0.000 description 2
- DXTOOBDIIAJZBJ-BQBZGAKWSA-N Pro-Gly-Ser Chemical compound [H]N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CO)C(O)=O DXTOOBDIIAJZBJ-BQBZGAKWSA-N 0.000 description 2
- ABSSTGUCBCDKMU-UWVGGRQHSA-N Pro-Lys-Gly Chemical compound NCCCC[C@@H](C(=O)NCC(O)=O)NC(=O)[C@@H]1CCCN1 ABSSTGUCBCDKMU-UWVGGRQHSA-N 0.000 description 2
- DCHQYSOGURGJST-FJXKBIBVSA-N Pro-Thr-Gly Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O DCHQYSOGURGJST-FJXKBIBVSA-N 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- RHAPJNVNWDBFQI-BQBZGAKWSA-N Ser-Pro-Gly Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O RHAPJNVNWDBFQI-BQBZGAKWSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- MSIYNSBKKVMGFO-BHNWBGBOSA-N Thr-Gly-Pro Chemical compound C[C@H]([C@@H](C(=O)NCC(=O)N1CCC[C@@H]1C(=O)O)N)O MSIYNSBKKVMGFO-BHNWBGBOSA-N 0.000 description 2
- RFKVQLIXNVEOMB-WEDXCCLWSA-N Thr-Leu-Gly Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)O)N)O RFKVQLIXNVEOMB-WEDXCCLWSA-N 0.000 description 2
- JAWUQFCGNVEDRN-MEYUZBJRSA-N Thr-Tyr-Leu Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC(C)C)C(=O)O)N)O JAWUQFCGNVEDRN-MEYUZBJRSA-N 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- AVFGBGGRZOKSFS-KJEVXHAQSA-N Tyr-Met-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CC1=CC=C(C=C1)O)N)O AVFGBGGRZOKSFS-KJEVXHAQSA-N 0.000 description 2
- DNOOLPROHJWCSQ-RCWTZXSCSA-N Val-Arg-Thr Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O DNOOLPROHJWCSQ-RCWTZXSCSA-N 0.000 description 2
- XEYUMGGWQCIWAR-XVKPBYJWSA-N Val-Gln-Gly Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)NCC(=O)O)N XEYUMGGWQCIWAR-XVKPBYJWSA-N 0.000 description 2
- 108010005233 alanylglutamic acid Proteins 0.000 description 2
- 108010087924 alanylproline Proteins 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 108010013835 arginine glutamate Proteins 0.000 description 2
- 235000019835 bromelain Nutrition 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 108010078144 glutaminyl-glycine Proteins 0.000 description 2
- 108010054666 glycyl-leucyl-glycyl-glycine Proteins 0.000 description 2
- 108010050848 glycylleucine Proteins 0.000 description 2
- 108010015792 glycyllysine Proteins 0.000 description 2
- 108010077515 glycylproline Proteins 0.000 description 2
- 108010037850 glycylvaline Proteins 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 108010028295 histidylhistidine Proteins 0.000 description 2
- 108010057821 leucylproline Proteins 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 108010005942 methionylglycine Proteins 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 229940055729 papain Drugs 0.000 description 2
- 235000019834 papain Nutrition 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 108010077112 prolyl-proline Proteins 0.000 description 2
- 239000012460 protein solution Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- 108010061238 threonyl-glycine Proteins 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 229960001322 trypsin Drugs 0.000 description 2
- HAVKMRGWNXMCDR-STQMWFEESA-N Arg-Gly-Phe Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O HAVKMRGWNXMCDR-STQMWFEESA-N 0.000 description 1
- 235000019750 Crude protein Nutrition 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- JBRBACJPBZNFMF-YUMQZZPRSA-N Gly-Ala-Lys Chemical compound NCC(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCCCN JBRBACJPBZNFMF-YUMQZZPRSA-N 0.000 description 1
- PBLLTSKBTAHDNA-KBPBESRZSA-N Lys-Gly-Phe Chemical compound [H]N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O PBLLTSKBTAHDNA-KBPBESRZSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 1
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- SLUWOCTZVGMURC-BFHQHQDPSA-N Thr-Gly-Ala Chemical compound C[C@@H](O)[C@H](N)C(=O)NCC(=O)N[C@@H](C)C(O)=O SLUWOCTZVGMURC-BFHQHQDPSA-N 0.000 description 1
- AQAMPXBRJJWPNI-JHEQGTHGSA-N Thr-Gly-Glu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(O)=O AQAMPXBRJJWPNI-JHEQGTHGSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 108010029483 alpha 1 Chain Collagen Type I Proteins 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 102000034238 globular proteins Human genes 0.000 description 1
- 108091005896 globular proteins Proteins 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910001453 nickel ion Inorganic materials 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000014599 transmission of virus Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/32—Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
- A61L15/325—Collagen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/24—Collagen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/60—Materials for use in artificial skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/10—General cosmetic use
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/805—Corresponding aspects not provided for by any of codes A61K2800/81 - A61K2800/95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/86—Products or compounds obtained by genetic engineering
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/06—Materials or treatment for tissue regeneration for cartilage reconstruction, e.g. meniscus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/16—Materials or treatment for tissue regeneration for reconstruction of eye parts, e.g. intraocular lens, cornea
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- General Engineering & Computer Science (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Transplantation (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Birds (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Materials Engineering (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Plant Pathology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Peptides Or Proteins (AREA)
Abstract
The invention discloses a triple helix recombinant humanized type I collagen, a preparation method and application thereof, wherein the recombinant humanized type I collagen has a triple helix structure and a (Gly-X-Y) n repeated amino acid sequence which are characteristic of the collagen, and can be self-assembled to form collagen fibers with good morphology; the recombinant humanized type I collagen prepared by the invention has important functional sites of human type I collagen, shows good biocompatibility and bioactivity, and can obviously promote proliferation, adhesion and migration of human skin fibroblasts; the recombinant humanized type I collagen is prepared by expressing the genetically engineered bacteria, the process is simple and convenient, and the industrial production is easy to realize; the prepared three-helix recombinant humanized type I collagen with high bioactivity can be widely applied to the fields of skin repair dressing, implant, artificial skin, artificial bone, artificial cartilage, artificial cornea, biological material, medical instrument, cosmetics, health care products, food and the like.
Description
Technical Field
The invention belongs to the technical field of genetic engineering, and particularly relates to triple helix recombinant humanized type I collagen, a preparation method and application thereof.
Background
Collagen is the highest protein content in mammals, accounting for about 30% of the total protein. The collagen has a characteristic triple helix structure, and can self-assemble to form collagen fibers with good morphology. The collagen fibers are further assembled to form a fiber lattice structure, providing mechanical strength to connective tissue and providing a suitable environment for cell growth. Up to now, at least 40 more collagen chain-encoding genes have been found. These different collagen chains, combined in different ways, can form more than 20 different types of collagen molecules. Among them, type I collagen is the most abundant type of collagen in the human body, and is the main component of connective tissues such as skin, bone, tendon, etc.
The biological material with the type I collagen as the main raw material is widely applied in the fields of tissue engineering, regenerative medicine and the like. Type I collagen is currently mainly extracted by animal tissue. Different treatment methods and processes of acid, alkali or protease and the like have been developed to extract type I collagen from different tissues such as skin, tendon, bone and the like of animals such as cattle, pigs and the like. However, animal extraction methods tend to destroy the triple helix structure and bioactivity of collagen, with the risk of potential viral transmission hazards. The recombinant collagen prepared by the genetic engineering technology can overcome the risks of batch quality difference, virus infection hidden trouble and the like of animal-derived collagen, so that the recombinant collagen gradually becomes a research hot spot. Transgenic plants, mammalian cells, bacteria, yeasts and the like are utilized to produce recombinant collagen, but expression systems of transgenic plants, mammalian cells and the like have high production cost and long period, and are difficult to meet the industrialization requirement. In contrast, the escherichia coli and yeast expression system has the advantages of low cost, high expression level and the like, and is the preferred mode of industrial production.
Regarding collagen, many researches have been made in the art, for example, chinese patent CN110903383a discloses a recombinant human type I collagen, coding gene, engineering bacteria and its application in preparing collagen preparation, the amino acid sequence of which is 9 times repeated as peptide GSKGDTGEPGPVGVQGPPGPAGEEGKRGARGEP; chinese patent CN113637068a provides a recombinant type I humanized collagen C1L5T, a preparation method and use, and its amino acid sequence includes peptide GEPGKQGPSGASGERGPPGPMGPPGLAGPPGESGREGAPGAEGSPGRDGSPGAKGDRGETGPAGPPGAPGAPGAPGPVGPAGKSGDRGETGPAGPAGPVGPVGARGPAGPQGPRGDKGETGEQGDRGIKGHRGFSGLQGPPGPPGSPGEQGPSGASGPAGPRGPPGSAGAPGKDGLNGLPGPTGPPGPRGRTGDAGPVGPPGPPGPPGPPGPP and terminal sequence peptide GAPGPCCGG of human type I collagen. Chinese patent CN105061589a provides a recombinant human type I collagen comprising a peptide stretch of human type I collagen α1 chain 660-964, 15 amino acids at position N-terminal 680-694, and 15 amino acids at position C-terminal 950-964 and a 3 group GER amino acid triplet. However, the recombinant type I collagen prepared by the methods lacks the three-helix structure, fiber morphology and biological function characteristic of collagen.
Aiming at the technical problems, the invention provides a triple helix recombinant humanized I-type collagen, a preparation method and application thereof. The recombinant humanized type I collagen has a triple helix structure which is characteristic of collagen, strictly adheres to Gly-X-Y repeated sequences by 100%, and can be self-assembled to form collagen fibers with good morphology; the recombinant humanized type I collagen has important functional sites of human type I collagen, shows excellent biocompatibility and bioactivity, and can remarkably promote proliferation, adhesion and migration of human skin fibroblasts; the recombinant humanized type I collagen is prepared by a genetic engineering bacterium expression and precursor collagen enzymolysis method, has a simple process, is convenient to operate, and is easy to realize industrial production; the recombinant humanized type I collagen can be widely applied to the fields of skin repair dressing, implant, artificial skin, artificial bone, artificial cartilage, artificial cornea, biological material, medical instrument, cosmetics, health care products, food and the like.
Disclosure of Invention
Aiming at the technical problems, the primary purpose of the invention is to provide triple helix recombinant humanized type I collagen, wherein the triple helix recombinant humanized type I collagen is collagen THRCI-1 or collagen THRCI-2, the amino acid sequence of the collagen THRCI-1 is shown as SEQ ID NO.1, and the amino acid sequence of the collagen THRCI-2 is shown as SEQ ID NO. 2.
Preferably, the recombinant humanized type I collagen is obtained after treating a precursor collagen with a protease; the amino acid sequence of precursor collagen 1 corresponding to collagen THRCI-1 is shown as SEQ ID NO.3, and the amino acid sequence of precursor collagen 2 corresponding to collagen THRCI-1 is shown as SEQ ID NO. 4.
Preferably, the gene sequence of the precursor collagen 1 corresponding to the collagen THRCI-1 is shown in SEQ ID NO.5, and the gene sequence of the precursor collagen 2 corresponding to the collagen THRCI-2 is shown in SEQ ID NO. 6.
Preferably, the protease comprises pepsin, trypsin, papain, bromelain, thrombin.
The invention also provides a recombinant vector or recombinant genetically engineered bacterium carrying the gene.
Preferably, the vector comprises pCold or pET.
Preferably, the engineering bacteria are escherichia coli.
The invention also provides a preparation method of the triple helix recombinant humanized type I collagen, which comprises the following steps:
(1) Synthesizing a gene sequence encoding the precursor collagen;
(2) Connecting the gene sequence in the step (1) with a vector, transforming bacteria, and constructing recombinant genetic engineering bacteria;
(3) Expressing the recombinant genetically engineered bacteria constructed in the step (2), collecting bacterial precipitate, crushing to obtain supernatant, and purifying to obtain precursor collagen;
(4) And (3) adding protease to treat the precursor collagen obtained in the step (3), and purifying to obtain the triple helix recombinant humanized type I collagen.
Preferably, the protease in step (4) comprises pepsin, trypsin, papain, bromelain, thrombin.
The invention also provides application of the triple helix recombinant humanized type I collagen in preparing skin repair dressing, implant, artificial skin, artificial bone, artificial cartilage, artificial cornea, biological material, medical instrument, cosmetics, health care product and food.
Compared with the prior art, the invention has the beneficial effects that: ① The invention provides a triple helix recombinant humanized type I collagen, wherein the amino acid sequence of the collagen is derived from a human type I collagen alpha 1 chain, and compared with the type I collagen from animal sources, the triple helix recombinant humanized type I collagen has the advantages of no hidden danger of virus transmission, low immunogenicity and the like; ② The recombinant humanized type I collagen provided by the invention has a triple helix structure characteristic of collagen and a (Gly-X-Y) n repeated amino acid sequence; ③ The triple helix recombinant humanized type I collagen provided by the invention can be self-assembled to form collagen fibers with good morphology and similar to natural collagen; ④ The triple helix recombinant humanized type I collagen provided by the invention has important functional sites of human type I collagen, has good biocompatibility and high biological activity, and can obviously promote proliferation, adhesion and migration of human skin fibroblasts (HFF-1); ⑤ The three-helix recombinant humanized I-type collagen gene engineering bacterium expression system provided by the invention has the advantages that the preparation process is simple and convenient, and the large-scale production is easy to realize; ⑥ The three-helix recombinant humanized type I collagen with high bioactivity prepared by the invention can be widely applied to the fields of skin repair dressing, implant, artificial skin, artificial bone, artificial cartilage, artificial cornea, biological material, medical equipment, cosmetics, health care products, food and the like.
Drawings
The foregoing and/or additional aspects and advantages of the present invention will be apparent and readily appreciated from the following description of the embodiments, taken in conjunction with the accompanying drawings.
FIG. 1 is a SDS-PAGE identification of triple helix recombinant humanized type I collagen
FIG. 2 is a two-level structure assay of triple helix recombinant humanized type I collagen
A, b, c are respectively a circular dichroism spectrum of THRCI-1, a circular dichroism spectrum thermal deformation curve and a first derivative (dθ/dT) of the thermal deformation curve; d, e, f are THRCI-2 circular dichroism spectrum, circular dichroism spectrum thermal curve and first derivative of thermal curve (dθ/dT), respectively
FIG. 3 is a Scanning Electron Microscope (SEM) image of triple helix recombinant humanized type I collagen
FIG. 4 is a diagram showing the proliferation of cells of triple helix recombinant humanized type I collagen
FIG. 5 is a diagram showing cell adhesion of triple helix recombinant humanized type I collagen
FIG. 6 is a cell migration diagram of triple helix recombinant humanized type I collagen
Detailed Description
The invention is further described in connection with the following detailed description, in order to make the technical means, the creation characteristics, the achievement of the purpose and the effect of the invention easy to understand. The scope of the invention is not limited to the examples described below.
The experimental materials in the following examples are commercially available unless otherwise specified.
EXAMPLE 1 preparation of recombinant humanized type I collagen
The amino acid sequences of the high-bioactivity triple helix recombinant humanized type I collagen THRCI-1 and the collagen THRCI-2 are respectively shown as SEQ ID NO.1 and SEQ ID NO.2, and the protein is obtained by treating precursor collagen with protease; the amino acid sequence of the precursor collagen 1 is shown as SEQ ID NO.3, the gene sequence is shown as SEQ ID NO.5, the amino acid sequence of the precursor collagen 2 is shown as SEQ ID NO.4, and the gene sequence is shown as SEQ ID NO. 6.
1. The amino acid sequence of the precursor collagen is determined to be shown as SEQ ID NO.3 and SEQ ID NO. 4;
2. Construction of precursor collagen expression strains:
Synthesizing a gene sequence of the precursor collagen as shown in SEQ ID NO.5 and SEQ ID NO.6, constructing a plasmid for introducing the nucleic acid, and confirming successful synthesis of the plasmid through DNA sequencing; transforming the plasmid into an escherichia coli BL21-DE3 strain to obtain a precursor collagen expression strain, adding glycerol into the strain which is transformed successfully, and storing the strain in a refrigerator at-80 ℃;
3. preparation and purification of collagen:
Adding 20 mu L of bacterial liquid into 200mL of LB liquid medium containing antibiotics, carrying out enrichment culture on the bacterial liquid by a shaking table at a constant temperature of 37 ℃ overnight, transferring the bacterial liquid into 1L of LB liquid medium containing the antibiotics according to 2% of inoculation amount, and continuing the enrichment culture in the shaking table at the constant temperature of 37 ℃; when the OD 600 value reaches 0.8-1.0, adjusting the temperature of the shaking table to 25 ℃, adding 1mM IPTG with the final concentration for induction expression, and culturing at constant temperature overnight; centrifuging the bacterial liquid in a low-temperature centrifuge at 3200rpm and 4 ℃ for 30min, and collecting bacterial cells.
The cells were dissolved in a buffer (20 mM sodium phosphate buffer, 20mM imidazole, 0.5M sodium chloride, pH 7.4), disrupted by a high-pressure homogenizer, the disrupted suspension was centrifuged again, and the supernatant, i.e., a crude protein solution, was further purified by a nickel ion affinity column to obtain a precursor collagen. And (3) adding pepsin with the final concentration of 0.008mg/mL to treat the precursor collagen, purifying to remove enzyme digestion products, and freeze-drying to obtain the triple helix recombinant humanized type I collagen with high bioactivity.
The highly bioactive triple helix recombinant humanized type I collagen prepared in example 1 was subjected to SDS-PAGE identification.
FIG. 1 shows that the recombinant humanized type I collagen THRCI-1 and the recombinant humanized type I collagen THRCI-2 prepared are single bands, indicating that the recombinant humanized type I collagen with high purity is successfully prepared. Due to the specific amino acid sequence and structure of collagen, migration rate on SDS-PAGE is less than that of globular proteins of the same molecular weight.
EXAMPLE 2 determination of the secondary Structure of recombinant humanized type I collagen
Round dichroism is a common method used to characterize protein structures. The recombinant humanized type I collagen prepared in example 1 was prepared as a 1mg/mL solution, and circular dichromatic full wavelength (190-260 nm) scans were performed at 4℃using a 1mm cuvette, with 1nm wavelength intervals, and 5s at each wavelength. The thermal profile was measured at 220nm and the temperature was from 4℃to 70 ℃. The rate of temperature increase is as follows: 4 ℃ -20 ℃ (1 ℃/min); 20 ℃ -50 ℃ (0.3 ℃/min); 50 ℃ -70 ℃ (1 ℃/min).
As shown in FIG. 2, both the recombinant humanized type I collagen THRCI-1 and the recombinant humanized type I collagen THRCI-2 showed an absorption peak characteristic of collagen around 225nm, indicating that the recombinant humanized type I collagen forms a triple helix structure. Thermal profile studies further showed that the recombinant humanized type I collagen THRCI-1 and recombinant humanized type I collagen THRCI-2 formed stable triple helix structures with thermal temperatures of 40℃and 42℃respectively.
EXAMPLE 3 Assembly morphology of recombinant humanized type I collagen
Recombinant humanized type I collagen THRCI-1 and recombinant humanized type I collagen THRCI-2 prepared in example 1 were dissolved with 20mM PB to a final concentration of 3mg/mL, left at 4℃for at least 12hrs, a small amount of the droplets were taken and placed on a silicon wafer until completely dried, and the dried samples were subjected to a2 minute metal spraying treatment before characterization by Hitachi S-4800 Scanning Electron Microscope (SEM).
As shown in FIG. 3, the recombinant humanized type I collagen THRCI-1 and the recombinant humanized type I collagen THRCI-2 self-assemble to form collagen fibers with good morphology and similar to natural collagen.
EXAMPLE 4 bioactivity of recombinant humanized type I collagen
(1) Cell proliferation assay
100 Mu L of human skin fibroblast HFF-1 with the cell density of 1X 10 5 per mL is added into a 96-well plate, the culture solution in the 96-well plate is sucked out after incubation for 24 hours at 37 ℃ and 5% CO 2, the recombinant humanized type I collagen prepared in the example 1 and the tissue extracted bovine type I collagen are prepared into a 0.1mg/mL collagen solution by using a DMEM high sugar culture medium, the collagen solution is added into the 96-well plate, a control group is only added with the DMEM high sugar culture medium, and the culture is continued to be incubated for 1, 3 and 5 days in a 5% CO 2 incubator at 37 ℃. The designed recombinant humanized I collagen is used for detecting the proliferation effect of human skin fibroblast HFF-1.
As shown in FIG. 4, the recombinant humanized type I collagen THRCI-1 and the recombinant humanized type I collagen THRCI-2 have remarkable effect of promoting proliferation of human skin fibroblast HFF-1 and are superior to bovine type I collagen extracted from tissues.
(2) Cell adhesion experiments
The recombinant humanized type I collagen prepared in example 1 was prepared into a collagen solution of 0.1mg/mL using PBS, heat denatured 1% BSA and bovine type I collagen standard of 0.1mg/mL were used as a negative control and a positive control, respectively, each of the above protein solutions was added to a 24-well plate to be adsorbed at 4℃for 24 hours, and then the solution was aspirated. Human skin fibroblasts HFF-1 were diluted to a density of 1X 10 5 cells/mL with DMEM high-sugar medium, 500. Mu.L cells were added to each well, and cell adhesion was observed under a microscope after 6 hours.
As shown in fig. 5, both the recombinant humanized type I collagen THRCI-1 and the recombinant humanized type I collagen THRCI-2 showed good cell adhesion effect and excellent cell adhesion performance compared to BSA.
(3) Cell migration experiments
The cell migration promoting effect of the recombinant humanized type I collagen prepared in example 1 was measured by using a cell scratch method. 3 lines were drawn transversely per well behind a 6-well plate with a marker pen, the line spacing being 0.5-1cm. 2mL HFF-1 cells with a cell density of 2.5X10 5/mL were seeded in the 6-well plate to ensure that the cell culture was able to reach 95% -100% confluency after 24 h. After 24 hours, the well plate was aligned with a 10. Mu.L tip and a scratch was formed by gently pushing down in the longitudinal direction, and the recombinant humanized type I collagen prepared in example 1 was prepared with DMEM high-sugar medium to a collagen solution of 0.1mg/mL, DMEM high-sugar medium and 0.1mg/mL bovine type I collagen as a negative control and a positive control, respectively. The change in scratch area was recorded under an inverted fluorescence microscope for 0h and 24 h.
As shown in fig. 6, both the recombinant humanized type I collagen THRCI-1 and the recombinant humanized type I collagen THRCI-2 exhibited good cell migration promoting effect compared to the blank.
The experimental result shows that the recombinant humanized type I collagen prepared by the invention has a triple helix structure and (Gly-X-Y) n repeated amino acid sequence which are characteristic of collagen, and can be self-assembled to form collagen fibers with good morphology; the recombinant humanized type I collagen prepared by the invention has important functional sites of human type I collagen, shows good biocompatibility and bioactivity, and can obviously promote proliferation, adhesion and migration of human skin fibroblasts; the recombinant humanized type I collagen is prepared by expressing the genetically engineered bacteria, the process is simple and convenient, and the industrial production is easy to realize; the three-helix recombinant humanized type I collagen with high bioactivity prepared by the invention can be widely applied to the fields of skin repair dressing, implant, artificial skin, artificial bone, artificial cartilage, artificial cornea, biological material, medical equipment, cosmetics, health care products, food and the like.
The foregoing is merely illustrative of the details of the individual exemplary embodiments of the invention, and it will be apparent to those skilled in the art that the invention may be varied and modified in practice depending on the particular manufacturing conditions and is not intended to be limiting. It is intended that all such modifications within the spirit and principles of the invention be included within the scope of the invention.
Sequence listing
<110> Collagen (Wuhan) biotechnology Co.Ltd
<120> A triple helix recombinant humanized type I collagen, a preparation method and application thereof
<160> 6
<170> SIPOSequenceListing 1.0
<210> 1
<211> 168
<212> PRT
<213> Artificial sequence (ARTIFICIAL SEQUENCE)
<400> 1
Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly
1 5 10 15
Pro Pro Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly Glu
20 25 30
Arg Gly Pro Pro Gly Pro Gln Gly Ala Arg Gly Leu Pro Gly Ala Pro
35 40 45
Gly Gln Met Gly Pro Arg Gly Leu Pro Gly Glu Arg Gly Arg Pro Gly
50 55 60
Ala Pro Gly Pro Ala Gly Ala Arg Gly Glu Pro Gly Ala Pro Gly Ser
65 70 75 80
Lys Gly Asp Thr Gly Ala Lys Gly Phe Pro Gly Glu Arg Gly Val Gln
85 90 95
Gly Pro Pro Gly Pro Ala Gly Glu Glu Gly Lys Arg Gly Ala Arg Gly
100 105 110
Glu Pro Gly Pro Thr Gly Pro Ala Gly Pro Lys Gly Ser Pro Gly Glu
115 120 125
Ala Gly Arg Pro Gly Glu Ala Gly Leu Pro Gly Pro Pro Gly Pro Pro
130 135 140
Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly
145 150 155 160
Pro Pro Gly Pro Pro Gly Pro Pro
165
<210> 2
<211> 168
<212> PRT
<213> Artificial sequence (ARTIFICIAL SEQUENCE)
<400> 2
Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly
1 5 10 15
Pro Pro Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly Glu
20 25 30
Arg Gly Pro Pro Gly Pro Gln Gly Ala Arg Gly Leu Pro Gly Ala Pro
35 40 45
Gly Gln Met Gly Pro Arg Gly Leu Pro Gly Glu Arg Gly Arg Pro Gly
50 55 60
Ala Pro Gly Pro Ala Gly Ala Arg Gly Glu Pro Gly Ala Pro Gly Ser
65 70 75 80
Lys Gly Asp Thr Gly Glu Arg Gly Phe Pro Gly Glu Arg Gly Val Gln
85 90 95
Gly Pro Pro Gly Pro Ala Gly Glu Glu Gly Lys Arg Gly Ala Arg Gly
100 105 110
Glu Pro Gly Pro Thr Gly Pro Ala Gly Pro Lys Gly Ser Pro Gly Glu
115 120 125
Ala Gly Arg Pro Gly Glu Ala Gly Leu Pro Gly Pro Pro Gly Pro Pro
130 135 140
Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly
145 150 155 160
Pro Pro Gly Pro Pro Gly Pro Pro
165
<210> 3
<211> 253
<212> PRT
<213> Artificial sequence (ARTIFICIAL SEQUENCE)
<400> 3
Met His His His His His His Ala Asp Glu Gln Glu Glu Lys Ala Lys
1 5 10 15
Val Arg Thr Glu Leu Ile Gln Glu Leu Ala Gln Gly Leu Gly Gly Phe
20 25 30
Glu Lys Lys Asn Phe Pro Thr Leu Gly Asp Glu Asp Leu Asp His Thr
35 40 45
Tyr Met Thr Lys Leu Leu Thr Tyr Leu Gln Glu Arg Glu Gln Ala Glu
50 55 60
Asn Ser Trp Arg Lys Arg Leu Leu Lys Gly Ile Gln Asp His Ala Leu
65 70 75 80
Asp Leu Val Pro Arg Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly Pro
85 90 95
Pro Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly Pro Pro
100 105 110
Gly Pro Pro Gly Glu Arg Gly Pro Pro Gly Pro Gln Gly Ala Arg Gly
115 120 125
Leu Pro Gly Ala Pro Gly Gln Met Gly Pro Arg Gly Leu Pro Gly Glu
130 135 140
Arg Gly Arg Pro Gly Ala Pro Gly Pro Ala Gly Ala Arg Gly Glu Pro
145 150 155 160
Gly Ala Pro Gly Ser Lys Gly Asp Thr Gly Ala Lys Gly Phe Pro Gly
165 170 175
Glu Arg Gly Val Gln Gly Pro Pro Gly Pro Ala Gly Glu Glu Gly Lys
180 185 190
Arg Gly Ala Arg Gly Glu Pro Gly Pro Thr Gly Pro Ala Gly Pro Lys
195 200 205
Gly Ser Pro Gly Glu Ala Gly Arg Pro Gly Glu Ala Gly Leu Pro Gly
210 215 220
Pro Pro Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly Pro
225 230 235 240
Pro Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly Pro Pro
245 250
<210> 4
<211> 253
<212> PRT
<213> Artificial sequence (ARTIFICIAL SEQUENCE)
<400> 4
Met His His His His His His Ala Asp Glu Gln Glu Glu Lys Ala Lys
1 5 10 15
Val Arg Thr Glu Leu Ile Gln Glu Leu Ala Gln Gly Leu Gly Gly Phe
20 25 30
Glu Lys Lys Asn Phe Pro Thr Leu Gly Asp Glu Asp Leu Asp His Thr
35 40 45
Tyr Met Thr Lys Leu Leu Thr Tyr Leu Gln Glu Arg Glu Gln Ala Glu
50 55 60
Asn Ser Trp Arg Lys Arg Leu Leu Lys Gly Ile Gln Asp His Ala Leu
65 70 75 80
Asp Leu Val Pro Arg Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly Pro
85 90 95
Pro Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly Pro Pro
100 105 110
Gly Pro Pro Gly Glu Arg Gly Pro Pro Gly Pro Gln Gly Ala Arg Gly
115 120 125
Leu Pro Gly Ala Pro Gly Gln Met Gly Pro Arg Gly Leu Pro Gly Glu
130 135 140
Arg Gly Arg Pro Gly Ala Pro Gly Pro Ala Gly Ala Arg Gly Glu Pro
145 150 155 160
Gly Ala Pro Gly Ser Lys Gly Asp Thr Gly Glu Arg Gly Phe Pro Gly
165 170 175
Glu Arg Gly Val Gln Gly Pro Pro Gly Pro Ala Gly Glu Glu Gly Lys
180 185 190
Arg Gly Ala Arg Gly Glu Pro Gly Pro Thr Gly Pro Ala Gly Pro Lys
195 200 205
Gly Ser Pro Gly Glu Ala Gly Arg Pro Gly Glu Ala Gly Leu Pro Gly
210 215 220
Pro Pro Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly Pro
225 230 235 240
Pro Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly Pro Pro
245 250
<210> 5
<211> 759
<212> DNA
<213> Artificial sequence (ARTIFICIAL SEQUENCE)
<400> 5
atgcatcacc accaccacca tgctgatgaa caagaagaga aggcaaaggt gcgtaccgaa 60
ctgatccaag agctggcaca gggtcttggt ggtttcgaaa agaagaactt tccgacgctg 120
ggtgatgaag atctggacca tacctacatg accaaactgt tgacctatct ccaagaacgt 180
gaacaggcag aaaatagctg gcgtaaacgc ctgttaaaag gcattcaaga ccacgccctg 240
gatttggttc cgagaggccc gccgggcccg cccggcccgc cgggcccgcc gggtccgccg 300
ggcccgccgg gaccgccggg tcctccgggc ccaccgggcc cgccggggga gcgcggtccg 360
ccgggcccac agggcgcccg tggtttgccg ggcgcgcctg gtcagatggg tccgcgtggc 420
ctgccgggcg agcgcggtcg tccgggcgcg ccaggcccag cgggtgcgcg tggtgaaccg 480
ggcgctccgg gctccaaagg cgacaccggt gcgaagggct tcccgggtga gcgcggtgtc 540
cagggcccac cgggcccggc gggtgaggaa ggtaaacgtg gtgctcgcgg tgagccgggt 600
ccgactggtc cggctggtcc gaaaggtagc ccgggggagg cgggtcgtcc gggtgaggcg 660
ggtctgccgg gtccaccggg tccgccgggc cccccgggcc ctccgggccc accgggtccg 720
ccaggcccgc cgggtccgcc gggcccgcct ggcccgccg 759
<210> 6
<211> 759
<212> DNA
<213> Artificial sequence (ARTIFICIAL SEQUENCE)
<400> 6
atgcatcacc accaccacca tgctgatgaa caagaggaaa aggcgaaagt tcgtaccgaa 60
ctgattcaag aactggctca gggtttaggt ggtttcgaga agaagaattt tccgaccctg 120
ggtgatgaag atctggacca cacctacatg accaagctgt tgacctatct gcaagagcgt 180
gaacaggcag aaaacagctg gcgtaaacgt ctgttgaagg gcatccaaga tcatgcactg 240
gacttggtcc cgagaggtcc gccgggcccg ccgggtccgc cgggtccgcc gggtccgccg 300
ggtcccccgg gtccgccagg cccgccgggt ccgccgggcc cgccgggcga gcgtggtccg 360
ccgggcccac agggcgctcg cggtcttccg ggtgcccctg gccagatggg tccgcgtggt 420
ctgccgggtg agcgcggtcg cccaggcgcg ccaggcccgg ctggtgcgcg tggtgaaccg 480
ggcgcgccgg gcagcaaagg cgacactggt gagcgcggat tcccgggtga gcgcggggtg 540
cagggtccgc cgggcccggc cggtgaggaa ggtaaacgtg gcgcgcgtgg tgagccgggc 600
ccaacgggtc cggcgggtcc gaaaggttcc ccgggcgaag caggcagacc tggcgaggcg 660
ggtctcccgg gccctccggg tccgccgggt cctccgggcc cgccgggccc gccgggcccg 720
ccgggcccac caggcccgcc aggtccgccg ggcccgccg 759
Claims (9)
1. The triple helix recombinant humanized type I collagen is collagen THRCI-1 or collagen THRCI-2, the amino acid sequence of the collagen THRCI-1 is shown as SEQ ID NO.1, and the amino acid sequence of the collagen THRCI-2 is shown as SEQ ID NO. 2.
2. A recombinant vector or recombinant genetically engineered bacterium carrying a gene sequence encoding the collagen amino acid sequence of claim 1.
3. The recombinant vector or recombinant genetically engineered bacterium of claim 2, wherein the vector comprises pCold or pET.
4. The recombinant vector or recombinant genetically engineered bacterium of claim 2, wherein the engineered bacterium is e.
5. The method for preparing triple helix recombinant humanized type I collagen according to claim 1, comprising the steps of:
(1) Synthesizing a gene sequence encoding a precursor collagen 1 corresponding to collagen THRCI-1 or a precursor collagen 2 corresponding to collagen THRCI-2 according to claim 1;
(2) Connecting the gene sequence in the step (1) with a vector, transforming bacteria, and constructing recombinant genetic engineering bacteria;
(3) Expressing the recombinant genetically engineered bacteria constructed in the step (2), collecting bacterial precipitate, crushing to obtain supernatant, and purifying to obtain precursor collagen;
(4) Adding protease to treat the precursor collagen obtained in the step (3), and purifying to obtain triple helix recombinant humanized type I collagen;
The gene sequence of precursor collagen 1 corresponding to collagen THRCI-1 in the step (1) is shown as SEQ ID NO.5, and the gene sequence of precursor collagen 2 corresponding to collagen THRCI-2 is shown as SEQ ID NO. 6; the amino acid sequence of precursor collagen 1 corresponding to collagen THRCI-1 is shown as SEQ ID NO.3, and the amino acid sequence of precursor collagen 2 corresponding to collagen THRCI-2 is shown as SEQ ID NO. 4;
The protease in the step (4) is pepsin.
6. Use of the triple helix recombinant humanized type I collagen according to claim 1 for the preparation of skin repair dressings, implants, biomaterials, medical devices.
7. The use of claim 6, wherein the biological material is artificial skin, artificial bone or artificial cornea.
8. The use of claim 7, wherein the artificial bone is artificial cartilage.
9. The use of the triple helix recombinant humanized type I collagen according to claim 1 in the preparation of cosmetics.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210630810.XA CN115521373B (en) | 2022-06-06 | 2022-06-06 | Triple helix recombinant humanized type I collagen, preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210630810.XA CN115521373B (en) | 2022-06-06 | 2022-06-06 | Triple helix recombinant humanized type I collagen, preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115521373A CN115521373A (en) | 2022-12-27 |
| CN115521373B true CN115521373B (en) | 2024-04-19 |
Family
ID=84696240
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210630810.XA Active CN115521373B (en) | 2022-06-06 | 2022-06-06 | Triple helix recombinant humanized type I collagen, preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115521373B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115991764B (en) * | 2023-03-21 | 2023-06-09 | 杭州因智拓生物技术有限公司 | Hydroxyproline modified recombinant III type humanized collagen and preparation method and application thereof |
| CN117069827B (en) * | 2023-10-17 | 2023-12-22 | 北京世纪伟信医药科技有限公司 | Expression and application of recombinant collagen repetitive sequence protein |
| CN117903292A (en) * | 2024-03-19 | 2024-04-19 | 如凤凰再生科技发展(成都)有限公司 | Triple helix collagen with thermal stability and preparation method and application thereof |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105061589A (en) * | 2015-08-26 | 2015-11-18 | 华南理工大学 | Recombinant human I type collagen and immobilized fermentation production method thereof |
| CN108059184A (en) * | 2017-12-28 | 2018-05-22 | 兰州大学 | A kind of method that ZnO nanoparticle is prepared using recombined collagen as biomineralization template |
| CN110903383A (en) * | 2019-11-21 | 2020-03-24 | 郭伟 | Recombinant human type I collagen, encoding gene, engineering bacterium and application thereof |
| WO2020127929A1 (en) * | 2018-12-21 | 2020-06-25 | Gelita Ag | Synthetic and recombinant collagen peptides having biological activity |
| CN111499729A (en) * | 2020-04-23 | 2020-08-07 | 江南大学 | Method for regulating and controlling type I collagen fiber fringe period length |
| WO2021224316A1 (en) * | 2020-05-06 | 2021-11-11 | Gelita Ag | Expression of collagen peptide components in procaryotic systems |
| CN113637068A (en) * | 2021-09-15 | 2021-11-12 | 山西锦波生物医药股份有限公司 | Recombinant I-type humanized collagen C1L5T, and preparation method and application thereof |
| CN115521372A (en) * | 2022-05-31 | 2022-12-27 | 胶原蛋白(武汉)生物科技有限公司 | Triple-helix recombinant humanized type III collagen, preparation method and application |
-
2022
- 2022-06-06 CN CN202210630810.XA patent/CN115521373B/en active Active
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105061589A (en) * | 2015-08-26 | 2015-11-18 | 华南理工大学 | Recombinant human I type collagen and immobilized fermentation production method thereof |
| CN108059184A (en) * | 2017-12-28 | 2018-05-22 | 兰州大学 | A kind of method that ZnO nanoparticle is prepared using recombined collagen as biomineralization template |
| WO2020127929A1 (en) * | 2018-12-21 | 2020-06-25 | Gelita Ag | Synthetic and recombinant collagen peptides having biological activity |
| CN110903383A (en) * | 2019-11-21 | 2020-03-24 | 郭伟 | Recombinant human type I collagen, encoding gene, engineering bacterium and application thereof |
| CN111499729A (en) * | 2020-04-23 | 2020-08-07 | 江南大学 | Method for regulating and controlling type I collagen fiber fringe period length |
| WO2021224316A1 (en) * | 2020-05-06 | 2021-11-11 | Gelita Ag | Expression of collagen peptide components in procaryotic systems |
| CN113637068A (en) * | 2021-09-15 | 2021-11-12 | 山西锦波生物医药股份有限公司 | Recombinant I-type humanized collagen C1L5T, and preparation method and application thereof |
| CN115521372A (en) * | 2022-05-31 | 2022-12-27 | 胶原蛋白(武汉)生物科技有限公司 | Triple-helix recombinant humanized type III collagen, preparation method and application |
Non-Patent Citations (2)
| Title |
|---|
| Fluorescence self-quenching assay for the detection of target collagen sequences using a short probe peptide;Linge Nian等;Talanta;20180101(第176期);492-498 * |
| 胶原及其产物在皮肤老化及皮肤修复中的应用;王佳曼等;中国美容医学;20120131;21(1);176-178 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115521373A (en) | 2022-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN115521373B (en) | Triple helix recombinant humanized type I collagen, preparation method and application thereof | |
| EP4053160A1 (en) | Human collagen 17-type polypeptide, production method therefor and use thereof | |
| CN109575126B (en) | Polypeptides, method for the production and use thereof | |
| CN111334512A (en) | Recombinant human-like collagen containing hydroxyproline and hydroxylysine and production method thereof | |
| CN104402975B (en) | Anti-aging small peptide and preparation method thereof | |
| JP2024050477A (en) | Recombinant humanized collagen and its applications | |
| CN111423516B (en) | Protein and application thereof in wound repair and bacteriostasis | |
| CN116836263B (en) | Recombinant human-derived type iii collagen and pichia pastoris recombinant expression system thereof | |
| CN110172433B (en) | Recombinant bacillus subtilis engineering bacterium for producing porcine epidermal growth factor and application thereof | |
| CN116554309A (en) | Recombinant human III type collagen and preparation method and application thereof | |
| CN115819557B (en) | Triple helix recombinant humanized type II collagen, preparation method and application | |
| CN113025599B (en) | Recombinant clostridium histolyticum type I collagenase as well as preparation method and application thereof | |
| CN116333094A (en) | Recombinant humanized type I collagen alpha 1, expression vector and application | |
| CN105602878A (en) | Hyaluronidase cell surface display system and preparation and application thereof | |
| CN115521372B (en) | Triple helix recombinant humanized III type collagen, preparation method and application | |
| CN113880941B (en) | Recombinant humanized IxIII collagen, expression strain and application thereof | |
| CN117466992B (en) | Fibronectin mutant and preparation and application thereof | |
| CN115819557A (en) | Triple-helix recombinant humanized type II collagen, preparation method and application | |
| CN110627889B (en) | Recombinant spider silk protein, preparation method and industrial application thereof | |
| CN101603051A (en) | Utilize duckweed lemna minor production to be used for the treatment of the antibacterial peptide of infection | |
| CN115521372A (en) | Triple-helix recombinant humanized type III collagen, preparation method and application | |
| CN112625139B (en) | Protein and application thereof in promoting migration of skin fibroblasts, resisting bacteria and repairing wounds | |
| CN114292834B (en) | Fusion protease, preparation method thereof, application of fusion protease in extraction of type I collagen and application of type I collagen | |
| CN117466992A (en) | Fibronectin mutant and preparation and application thereof | |
| CN117285616B (en) | Recombinant humanized I+III type collagen and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |